HEALTHIER CHINA THROUGH INNOVATION

Under the China Association of Enterprises with Foreign Investment (CAEFI), the R&D-based Pharmaceutical Association Committee (RDPAC) is a non-profit organization made up of 44 member companies with pharmaceutical R&D capability.


RDPAC Announces Membership Succession of Executive Committee 2022-2023

May 25, 2022
The R&D-based Pharmaceutical Association Committee (RDPAC) has announced a change in membership of the RDPAC Executive Committee 2022-2023.

Paying for Innovation to Secure Payback - To Build a Value-oriented Innovative Payment System

April 22, 2022
The 2022 Jinling Pharmoeconomics Forum and the Annual Conference of Pharmoeconomics Committee, Jiangsu Pharmaceutical Association were held online on April 16-17.

Developing an Innovative Multi-Layered Security System for Rare Diseases Drugs and Establishing a Drug Value Assessment Mechanism

December 23, 2021
Healthcare Security Policy Sub-Forum of 2021 China Conference on Rare Diseases Successfully Held

PUBLICATIONS

DEEPENING THE DRUG INNOVATION ECOSYSTEM REFORM – A PLAN TO DESIGN AND BUILD CHINA’S CLINICAL RESEARCH SYSTEM

Health is the common aspiration of all mankind, and a healthy China constitutes an integral part of the “China Dream”.